AI predicts chemotherapy response in HR+/HER2- breast cancer
Part of Cancer, Skin clinical trials.
This trial uses AI to analyze your pre-treatment MRI and predict how well your tumor will respond to chemotherapy before surgery. It is for people with HR+/HER2- breast cancer who need chemo before their operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have invasive breast cancer that is hormone receptor positive (ER or PR at least 1%) and HER2-negative.
- Your cancer is stage II or III and you need chemotherapy before surgery.
- You have had a breast MRI with contrast before starting chemo, and the images are good enough for AI analysis.
- You have not received any other anti-cancer treatment for this breast cancer before this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses an artificial intelligence model to predict how well breast cancer responds to neoadjuvant therapy (treatment before surgery). It aims to improve treatment planning by analyzing MRI scans taken before and after therapy.
This study uses an AI model to predict how well chemotherapy will work before breast cancer surgery. It looks back at medical records and images from women who have already completed treatment to see if the AI can help guide future care.
This study tests whether an AI tool can predict how well breast cancer responds to chemotherapy given before surgery. Your tumor sample from a needle biopsy will be analyzed to see if the AI's prediction matches your actual treatment outcome.
This trial uses a special PET/MRI scan combined with artificial intelligence to see if it can predict whether HER2-positive breast cancer will completely disappear after treatment given before surgery. The goal is to learn who might avoid surgery or get a more tailored approach.
This study tests whether an AI tool can predict how well stomach cancer responds to chemotherapy before surgery. It uses CT scans and biopsy images taken before treatment starts to see if the AI can help guide future care.
This trial uses artificial intelligence to analyze images of your tumor tissue to predict if breast cancer might spread to other parts of the body. It may help doctors better understand your individual risk and guide treatment decisions.
Hear when a new HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.